[A18-01] Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (HIV-infected children) - Benefit assessment according to §35a Social Code Book V
Last updated 16.04.2018
Commission awarded on 05.01.2018 by the Federal Joint Committee (G-BA).
Children's and adolescents' health
Children aged 6 to 12 years who are infected with HIV-1
No study data; added benefit not proven in comparison with the appropriate comparator therapy
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A15-61||Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide - Benefit assessment according to §35a Social Code Book V||Commission completed|